AIDS Healthcare Foundation files amended lawsuit against Glaxo
BY Advocate.com Editors
April 23 2003 11:00 PM ET
The AIDS Healthcare Foundation has filed an amended lawsuit in federal court against drugmaker GlaxoSmithKline, challenging the company's patents on three of its anti-HIV medications, Reuters Health reports. AHF's original lawsuit--claiming that several of Glaxo's patents were invalid and that its prices on the medications exorbitantly exceeded the company's licensing, manufacturing, and distribution costs--was dismissed last month, but the judge allowed for the refiling of an amended complaint.
The amended lawsuit, filed in U.S. district court in Los Angeles, says that because Glaxo's drugs Epivir (3TC), Retrovir (AZT), and Ziagen were partially developed with federal tax dollars, the company's exclusive patents on the medications are invalid. The suit also alleges that Glaxo has monopolized the anti-HIV drug market. Michael Weinstein, AHF president, said in a statement that the organization is appealing the lawsuit because Glaxo's high antiretroviral prices have "cost untold numbers [of] lives. Despite GlaxoSmithKline's attempts to dismiss our lawsuit as 'frivolous,' our complaint is very serious indeed." Glaxo officials called the amended lawsuit "without merit."
- Brad Pitt and Angelina Jolie Support Their Kid Wearing Suits
- #TBT: They Died in the Closet
- Did Nickelodeon Just Confirm Legend of Korra Same-Sex Romance?
- This Year's Coolest Straight People in Entertainment
- WATCH: Laverne Cox Caught in Middle of Screaming Match on The View
- Gay Comic Publisher Undaunted by Apple's iBook Censorship